BC Extra | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

Cellestia is developing what could be a first-in-class small molecule that prevents assembly of transcription factor complexes that activate oncogene expression, and has raised CHF20 million ($20.3 million) in a B round that’ll enable completion...
BC Innovations | Oct 18, 2018
Distillery Therapeutics


INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than...
BC Week In Review | Sep 8, 2017
Clinical News

Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

Cellestia Biotech AG (Basel, Switzerland) said it received Spanish regulatory approval to start an open-label Phase I/IIa trial of CB-103 to treat adults with Notch (NOTCH)-dependent advanced or metastatic solid tumors and hematological malignancies. The...
BioCentury | Apr 7, 2017
Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG ’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch...
Items per page:
1 - 4 of 4